Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01878344 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention

Study acronym: EASE-PRM-PCI
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Dec 2024 to Dec 2026v17
  2. Study completion date: Dec 2023 to Dec 2024v16
  3. Study completion date: May 2023 to Dec 2023v15
  4. Study completion date: Jun 2022 to May 2023v14
  5. Study completion date: Nov 2021 to Jun 2022v13
Show 11 earlier versionsHide 11 earlier versions
  1. Study completion date: Jun 2021 to Nov 2021v12
  2. Study completion date: Aug 2020 to Jun 2021v11
  3. Study completion date: Feb 2020 to Aug 2020v10
  4. Study completion date: Dec 2018 to Feb 2020v9
  5. Primary completion date: Jun 2016 to Jan 2018
    • Study completion date: Dec 2017 to Dec 2018
    v8
  6. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 200 to confirmed 100
    • Study completion date: Dec 2017
    • Site details revised
    v7
  7. Re-verified, no change to tracked fieldsv6
  8. Primary completion date: Jun 2015 to Jun 2016v5
  9. Enrollment target: 300 to 200v4
  10. Primary completion date: Jan 2015 to Jun 2015
    • Eligibility criteria revised
    v3
  11. Secondary endpoint revised
    • Eligibility criteria shortened, about 1 word
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to evaluate the effects of N-acetyl cysteine on major cardiac and cerebral events in patients undergoing primary percutaneous coronary intervention who have moderate to high risk for contrast induced nephropathy. In a sub-group of patients coronary flow reserve will be evaluated.
Trial Details
NCT Number NCT01878344
Lead Sponsor Suleyman Demirel University
Conditions
(from sponsor)		 Acute ST Segment Elevation Myocardial Infarction
Related terms ST Elevation Myocardial Infarction
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov